Global Carcinoembryonic Antigen (CEA) Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

  • receipt Report ID : 155232
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 102
  • list Pharmaceuticals and Healthcare

Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion.

Scope of the Report:

This report studies the Carcinoembryonic Antigen (CEA) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Carcinoembryonic Antigen (CEA) market by product type and applications/end industries.

Increasing consumption of alcohol and sedentary lifestyle are likely to boost the growth of colorectal cancer over the forecast period.

The global Carcinoembryonic Antigen (CEA) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Carcinoembryonic Antigen (CEA).

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Roche Diagnostics

Abbott Diagnostics

Quest Diagnostics

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

CD66a

CD66b

CD66c

CD66d

CD66e

CD66f

Market Segment by Applications, can be divided into

Colorectal Cancer

Pancreatic Cancer

Ovarian Cancer

Breast Cancer

Thyroid Cancer

Others

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Carcinoembryonic Antigen (CEA) Market Overview

1.1 Product Overview and Scope of Carcinoembryonic Antigen (CEA)

1.2 Classification of Carcinoembryonic Antigen (CEA) by Types

1.2.1 Global Carcinoembryonic Antigen (CEA) Revenue Comparison by Types (2017-2023)

1.2.2 Global Carcinoembryonic Antigen (CEA) Revenue Market Share by Types in 2017

1.2.3 CD66a

1.2.4 CD66b

1.2.5 CD66c

1.2.6 CD66d

1.2.7 CD66e

1.2.8 CD66f

1.3 Global Carcinoembryonic Antigen (CEA) Market by Application

1.3.1 Global Carcinoembryonic Antigen (CEA) Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Colorectal Cancer

1.3.3 Pancreatic Cancer

1.3.4 Ovarian Cancer

1.3.5 Breast Cancer

1.3.6 Thyroid Cancer

1.3.7 Others

1.4 Global Carcinoembryonic Antigen (CEA) Market by Regions

1.4.1 Global Carcinoembryonic Antigen (CEA) Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Carcinoembryonic Antigen (CEA) Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Carcinoembryonic Antigen (CEA) Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Carcinoembryonic Antigen (CEA) Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Carcinoembryonic Antigen (CEA) Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Carcinoembryonic Antigen (CEA) Status and Prospect (2013-2023)

1.5 Global Market Size of Carcinoembryonic Antigen (CEA) (2013-2023)

2 Manufacturers Profiles

2.1 Roche Diagnostics

2.1.1 Business Overview

2.1.2 Carcinoembryonic Antigen (CEA) Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Roche Diagnostics Carcinoembryonic Antigen (CEA) Revenue, Gross Margin and Market Share (2016-2017)

2.2 Abbott Diagnostics

2.2.1 Business Overview

2.2.2 Carcinoembryonic Antigen (CEA) Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Abbott Diagnostics Carcinoembryonic Antigen (CEA) Revenue, Gross Margin and Market Share (2016-2017)

2.3 Quest Diagnostics

2.3.1 Business Overview

2.3.2 Carcinoembryonic Antigen (CEA) Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Quest Diagnostics Carcinoembryonic Antigen (CEA) Revenue, Gross Margin and Market Share (2016-2017)

3 Global Carcinoembryonic Antigen (CEA) Market Competition, by Players

3.1 Global Carcinoembryonic Antigen (CEA) Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Carcinoembryonic Antigen (CEA) Players Market Share

3.2.2 Top 10 Carcinoembryonic Antigen (CEA) Players Market Share

3.3 Market Competition Trend

4 Global Carcinoembryonic Antigen (CEA) Market Size by Regions

4.1 Global Carcinoembryonic Antigen (CEA) Revenue and Market Share by Regions

4.2 North America Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

4.3 Europe Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

4.5 South America Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

5 North America Carcinoembryonic Antigen (CEA) Revenue by Countries

5.1 North America Carcinoembryonic Antigen (CEA) Revenue by Countries (2013-2018)

5.2 USA Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

5.3 Canada Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

5.4 Mexico Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

6 Europe Carcinoembryonic Antigen (CEA) Revenue by Countries

6.1 Europe Carcinoembryonic Antigen (CEA) Revenue by Countries (2013-2018)

6.2 Germany Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

6.3 UK Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

6.4 France Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

6.5 Russia Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

6.6 Italy Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Carcinoembryonic Antigen (CEA) Revenue by Countries

7.1 Asia-Pacific Carcinoembryonic Antigen (CEA) Revenue by Countries (2013-2018)

7.2 China Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

7.3 Japan Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

7.4 Korea Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

7.5 India Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

8 South America Carcinoembryonic Antigen (CEA) Revenue by Countries

8.1 South America Carcinoembryonic Antigen (CEA) Revenue by Countries (2013-2018)

8.2 Brazil Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

8.3 Argentina Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

8.4 Colombia Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Carcinoembryonic Antigen (CEA) by Countries

9.1 Middle East and Africa Carcinoembryonic Antigen (CEA) Revenue by Countries (2013-2018)

9.2 Saudi Arabia Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

9.3 UAE Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

9.4 Egypt Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

9.5 Nigeria Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

9.6 South Africa Carcinoembryonic Antigen (CEA) Revenue and Growth Rate (2013-2018)

10 Global Carcinoembryonic Antigen (CEA) Market Segment by Type

10.1 Global Carcinoembryonic Antigen (CEA) Revenue and Market Share by Type (2013-2018)

10.2 Global Carcinoembryonic Antigen (CEA) Market Forecast by Type (2018-2023)

10.3 CD66a Revenue Growth Rate (2013-2023)

10.4 CD66b Revenue Growth Rate (2013-2023)

10.5 CD66c Revenue Growth Rate (2013-2023)

10.6 CD66d Revenue Growth Rate (2013-2023)

10.7 CD66e Revenue Growth Rate (2013-2023)

10.8 CD66f Revenue Growth Rate (2013-2023)

11 Global Carcinoembryonic Antigen (CEA) Market Segment by Application

11.1 Global Carcinoembryonic Antigen (CEA) Revenue Market Share by Application (2013-2018)

11.2 Carcinoembryonic Antigen (CEA) Market Forecast by Application (2018-2023)

11.3 Colorectal Cancer Revenue Growth (2013-2018)

11.4 Pancreatic Cancer Revenue Growth (2013-2018)

11.5 Ovarian Cancer Revenue Growth (2013-2018)

11.6 Breast Cancer Revenue Growth (2013-2018)

11.7 Thyroid Cancer Revenue Growth (2013-2018)

11.8 Others Revenue Growth (2013-2018)

12 Global Carcinoembryonic Antigen (CEA) Market Size Forecast (2018-2023)

12.1 Global Carcinoembryonic Antigen (CEA) Market Size Forecast (2018-2023)

12.2 Global Carcinoembryonic Antigen (CEA) Market Forecast by Regions (2018-2023)

12.3 North America Carcinoembryonic Antigen (CEA) Revenue Market Forecast (2018-2023)

12.4 Europe Carcinoembryonic Antigen (CEA) Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Carcinoembryonic Antigen (CEA) Revenue Market Forecast (2018-2023)

12.6 South America Carcinoembryonic Antigen (CEA) Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Carcinoembryonic Antigen (CEA) Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Carcinoembryonic Antigen (CEA) Picture

Table Product Specifications of Carcinoembryonic Antigen (CEA)

Table Global Carcinoembryonic Antigen (CEA) and Revenue (Millio

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery